-
Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock)
Tuesday, September 15, 2015 - 3:20pm | 503Read More...Shares of Biogen Inc (NASDAQ: BIIB) have sold off since reaching the highs of $480.18 in March. Joseph Schwartz of Leerink maintained an Overweight rating on the stock. Schwartz nevertheless felt it necessary to lower his price target on the stock to $425 from a previous $464. In a report...
-
Is BioMarin A Buy Ahead Of This Important Data Release?
Monday, June 15, 2015 - 10:44am | 323Read More...In a report published Monday, Leerink analyst Joseph P. Schwartz reiterated an Outperform rating and price target of $136 on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The analyst believes that the stock's offers a positive risk/reward profile heading into the release of the BMN-111 data. The...
-
GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success
Wednesday, March 26, 2014 - 6:57am | 97Read More...On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target. Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50...
-
UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results
Monday, June 3, 2013 - 1:13pm | 138Read More...In a report published on Monday, Leerink analyst Joseph Schwartz reiterated an Outperform rating on BioMarin (NASDAQ: BMRN) and maintained a $70.00 price target on the release of its full Phase 1/2 data on poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors....
